Efdamrofusp alfa
Based on 1 publication(s) in Google Scholar
Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.89%
- CAS. Nr.: 2375661-82-6
- Molecular Weight:140.4 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Efdamrofusp alfa
MoreAlle VEGFR Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Efdamrofusp alfa (0.135 mg/mL; 0, 6, 12, or 24 h) suppresses endothelial cell migration and tube formation[1].
Efdamrofusp alfa (0-1000 μg/mL) inhibits complement activation in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human primary umbilical vein endothelial cell (HUVEC)
-
Concentration:0.135 mg/mL
-
Incubation Time:0, 6, 12, or 24 h
-
Result:Showed a 20.91% reduction in migration.
Efdamrofusp alfa (1.35 mg; single intravitreal injection) shows favorable safety profiles and exhibited antiangiogenetic efficacy in a nonhuman primate laser-induced CNV model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J mice[1]
-
Dosage:13.5 μg; 13.0 μg
-
Administration:3 days; 7days
-
Result:Significantly reduced C3d deposition.
Reduced vascular leakage at 7 days after laser-induced injury.
Significantly suppressed CNV formation 7 days after laser-induced injury.
Reduced the concentrations of vitreous VEGF-A.
-
Animal Model:Rhesus monkeys[1]
-
Dosage:1.35 mg
-
Administration:Single intravitreal injection
-
Result:Decreased the CNV leakage at 14 and 28 days and effectively reduced CNV volume 28 days.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
FLT1 (fms-related tyrosine kinase 1, vascular endothelial growth factor receptor 1, VEGFR-1, VEGFR, FLT, FRT, vascular permeability factor receptor)domain 2 fragment (14-204)-KDR (kinase insert domain receptor, vascular endothelial growth factor receptor 2, VEGFR2, VEGF-R2, FLK1, CD309)domain 3 fragment (206-308)-IGHG1 Fc (Fragment constant (205-431))-CR1 (complement receptor type 1, C3b/C4b receptor, C3BR, Knops blood group, KN, CD35)fragment (1-192)
ELISA, FACS, Functional assay
Chemical Information
-
CAS. Nr. 2375661-82-6
-
Appearance Liquid
-
Molecular Weight 140.4 kDa
-
Color Colorless to light yellow
-
SMILES
[Efdamrofusp alfa]
-
Synonyms
IBI302
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Reinheit & Dokumentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Efdamrofusp alfa Related Classifications
HY-P99905 Related Classifications
Powered by Bioz